ClinicalTrials.gg
CompletedNCT01513161TRK-820Updated Jan 20, 2012

Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

A Phase 3 interventional study of nalfurafine hydrochloride (TRK-820) and Placebo in Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis, sponsored by SK Chemicals Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-01-20.

Sponsored by SK Chemicals Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.

Enrollment
5th of 10
104 · median 99
Started
2008
with 1 other
Phase 3
3 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
SK Chemicals Co., Ltd.

Among the 10 studies testing TRK 820 in Pruritus, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 3 in phase 3, and was the 3rd registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About TRK 820

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing TRK 820 in Pruritus, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.

03

Conditions studied

  • Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

Browse trials for

Keywords

  • pruritus
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[At the time of obtaining the consent form]

  • Chronic renal failure patients who regularly receive hemodialysis three times a week and are not likely to have a serious treatment change or acute symptoms during the study period
  • Patients who received both of the drug pruritus treatments in section 1 and 2 below within one year before the day of singing consent form

    1. Systemic therapy of more than two consecutive weeks depending on antihistamine or antiallergic drugs falling under "prescription drugs with indication of pruritus" (oral drugs, injections, etc.)
    2. Local therapy depending on "prescription drugs with indication of pruritus" (ointment, etc.) or a moisturizer prescribed by a doctor (topical preparation, etc.)
  • Patients for whom all the conventional pruritus treatments in section (2) are not enough
  • Patients aged 20 years or older at time of signing the consent form

[At the time of enrollment]

  • Patients whose VAS scores are measured both after breakfast and dinner for five days or more of the last 7 days of the predose observation period and whose mean of whichever the higher VAS scores after breakfast or dinner is ≥50 mm
  • Patients whose whichever the higher VAS score after breakfast or dinner for the last 7 days during the preliminary observation day (measured VAS score if one is missing) is more than ≥20 mm for five days or more
  • Patients who are judged to have pruritus both during the day and at night for more than two days based on the Shiratori's severity criteria assessed by the subject at days of fifth and sixth hemodialysis and the day of hemodialysis after the completion of the predose observation period, and whose whichever the higher pruritis score measured during the day or at night is 3 (moderate) for two days or more

Exclusion criteria

Exclusion Criteria:

  • Patients with malignant tumor
  • Patients with depression, schizophrenia or dementia as complications
  • Patients who currently have class B or C hepatic cirrhosis as complications
  • Patients with hepatic or cardiovascular diseases which cannot be controlled by diet or drug therapy
  • Patients who currently have the following heart diseases: life-threatening arrhythmia; unstable angina or myocardiac infarction within 6 months; PCI or CABG within 6 months; class III or IV congestive heart failure
  • Patients with atopic dermatitis or chronic urticaria as complications
  • Patients who are allergic to opioid drugs
  • Patients with dependence on drug or alcohol
  • Patients who received phototherapy for pruritus within one month before signing the consent form
  • Patients who participated in the study of TRK-820 and received the study drug or who were already enrolled in this study
  • Patients who participated in other clinical studies (including the ones using artificial kidney and medical equipment), and received the study drug or treatment with clinical equipment within one month before signing the consent form
  • Pregnant women, lactating women and patients of who do not use methods
  • Patients who cannot report VAS scores by their own for any reason at the principal investigator or study personnel's discretion
  • Patients whose complications or history can impact the results of this study at the principal investigator or subinvestisator's discretion
  • Other patients who are not proper to participate in this study at the principal investigator or study personnel's discretion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Active comparator
    TRK-820 5μg

    Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days

    Drug: nalfurafine hydrochloride (TRK-820)

  • Active comparator
    TRK-820 2.5μg

    Taking TRK-820 2.5μg(one 2.5μg capsule \& one placebo capsule)by oral route once daily for 14 days

    Drug: nalfurafine hydrochloride (TRK-820)

  • Placebo comparator
    Placebo

    Taking Placebo(two placebo capsule) by oral route once daily for 14 days

    Drug: Placebo

Interventions

  • Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change in pruritus degree measured by VAS(Visual Analogue Scale) score

    Time frame: 4 weeks (2 weeks measurement with only conventional treatment + 2 weeks measurement with conventional treatment & investigational products)

Secondary outcomes

  1. Changes in Shiratori's severity scores assessed by the subject.

    Time frame: 4 weeks (2 weeks measurement with only conventional treatment + 2 weeks measurement with conventional treatment & investigational products)

07

Study locations

1 site
  • SKchemicals Investigational Site
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2. PubMed 33283264 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2010
First posted
Jan 20, 2012
Start
Apr 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Jan 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01513161
Collaborators
Toray Industries, Inc
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Apr 2008
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Jan 20, 2012

Study contacts

Suhng Gwon Kim, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK 820

Start the discussion